Arvinas promotes CBO to CEO Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Th Fri 13 February, 2026

After years of rough sledding, biotech investors are getting back to work. Join us for a data-driven look at the field’s top VCs and their strategies for 2026. Get your spot now.

presented by 7 Re­al-World Ways RWE Is Trans­form­ing Health­care

SPOTLIGHT Even Europeans don't see a future in Euro biopharma anymore: Endpoints Signal

news Ultragenyx to lay off about 130 employees after rough 2025 PTC Therapeutics withdraws US filing for troubled Duchenne treatment Peer Review Paul Hudson couldn’t quite get Sanofi over the hump; PROTAC developer Arvinas appoints CEO

CGT has fresh momentum from new FDA frameworks and pharma deals, but do the latest advances in science, manufacturing, and regulation actually solve the core challenges? We’re asking the hard questions — join us.

endpoints pharma Icon's stock drops 40% after disclosing internal accounting probe Controversy around FDA’s Prasad rises again after Moderna rejection, behavior allegations AbbVie sues Trump administration for selecting Botox in latest IRA round Cassidy bill seeks to ban a customs loophole on pharma's radar Pharma pushes back on FDA plans to ease prescription-OTC drug switches Novo Nordisk to expand Irish factory for Wegovy pill

Client Engagement Mgr - Life Sciences Strategy & Intelligence Sedulo Group United States Vice President, Drug Metabolism & Pharmacokinetics (DMPK) C4 Therapeutics Watertown, MA, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

in case you missed it 1. Sanofi’s new CEO Belén Garijo gets frosty reception as Dupixent challenge awaits •  Updated: Sanofi's Paul Hudson out, with Belén Garijo to step in as new CEO 2. Terray says its AI model beats a popular open-source model at predicting how molecules bind with proteins 3. In a first, one CAR-T therapy is going up directly against another in trial 4. BridgeBio's dwarfism drug succeeds in Phase 3, adding to recent late-stage wins 5. News Briefing A pancreatic cancer approval; Seres cuts staff 6.